{"title":"前列腺根治术与外束放疗治疗高危前列腺癌的比较。","authors":"Peerapon Sangthong, Nattapong Binsri, Sarayut Kanjanatarayon, Weerayut Wiriyabanditkul, Thanisorn Pattanasuwon, Satit Siriboonrid","doi":"10.4103/ua.ua_21_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the clinical outcome of high-risk prostate cancer patients receiving radical prostatectomy (RP) or radiotherapy (RT).</p><p><strong>Materials and methods: </strong>Patients were classified as high-risk prostate cancer and received definitive treatment between 2013 and 2023. Patients with previous pelvic RT and incomplete medical record were excluded. The primary outcomes were progression-free survival (PFS) and distant metastasis-free survival (MFS). The secondary outcomes were factors for progression and metastasis.</p><p><strong>Results: </strong>Of 244 patients analyzed (89 RP and 155 RT); the estimated 10-year PFS was 49.9% in the RP and 75.5% in the RT (<i>P</i> = 0.013). No significant difference was seen in the distant MFS (<i>P</i> = 0.177) and overall survival (<i>P</i> = 0.052). Univariate and multivariate were analyzed; the factor for progress or metastasis was initial prostate-specific antigen.</p><p><strong>Conclusion: </strong>Our data demonstrated that RT offers superiority over RP in PFS, whereas distant metastasis was similar.</p>","PeriodicalId":23633,"journal":{"name":"Urology Annals","volume":"17 3","pages":"144-148"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366844/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.\",\"authors\":\"Peerapon Sangthong, Nattapong Binsri, Sarayut Kanjanatarayon, Weerayut Wiriyabanditkul, Thanisorn Pattanasuwon, Satit Siriboonrid\",\"doi\":\"10.4103/ua.ua_21_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>We evaluated the clinical outcome of high-risk prostate cancer patients receiving radical prostatectomy (RP) or radiotherapy (RT).</p><p><strong>Materials and methods: </strong>Patients were classified as high-risk prostate cancer and received definitive treatment between 2013 and 2023. Patients with previous pelvic RT and incomplete medical record were excluded. The primary outcomes were progression-free survival (PFS) and distant metastasis-free survival (MFS). The secondary outcomes were factors for progression and metastasis.</p><p><strong>Results: </strong>Of 244 patients analyzed (89 RP and 155 RT); the estimated 10-year PFS was 49.9% in the RP and 75.5% in the RT (<i>P</i> = 0.013). No significant difference was seen in the distant MFS (<i>P</i> = 0.177) and overall survival (<i>P</i> = 0.052). Univariate and multivariate were analyzed; the factor for progress or metastasis was initial prostate-specific antigen.</p><p><strong>Conclusion: </strong>Our data demonstrated that RT offers superiority over RP in PFS, whereas distant metastasis was similar.</p>\",\"PeriodicalId\":23633,\"journal\":{\"name\":\"Urology Annals\",\"volume\":\"17 3\",\"pages\":\"144-148\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366844/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology Annals\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ua.ua_21_25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Annals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ua.ua_21_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.
Purpose: We evaluated the clinical outcome of high-risk prostate cancer patients receiving radical prostatectomy (RP) or radiotherapy (RT).
Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2013 and 2023. Patients with previous pelvic RT and incomplete medical record were excluded. The primary outcomes were progression-free survival (PFS) and distant metastasis-free survival (MFS). The secondary outcomes were factors for progression and metastasis.
Results: Of 244 patients analyzed (89 RP and 155 RT); the estimated 10-year PFS was 49.9% in the RP and 75.5% in the RT (P = 0.013). No significant difference was seen in the distant MFS (P = 0.177) and overall survival (P = 0.052). Univariate and multivariate were analyzed; the factor for progress or metastasis was initial prostate-specific antigen.
Conclusion: Our data demonstrated that RT offers superiority over RP in PFS, whereas distant metastasis was similar.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
